Data shows that metered cryospray therapy with the investigational RejuvenAir System leads to airway remodeling and improved symptoms in chronic bronchitis patients.
RT’s Three Key Takeaways:
- Airway Remodeling with Metered Cryospray: Data presented at the ERS Congress shows that metered cryospray therapy using the RejuvenAir System induces bronchial epithelial resurfacing and remodeling, leading to improved symptoms in chronic bronchitis patients.
- Reduction in Air-Trapping and Cellular Changes: The treatment demonstrated a reduction in air-trapping and changes in cellular populations, indicative of airway “rejuvenation” and improved lung function, providing evidence of the therapy’s efficacy in addressing chronic bronchitis.
- Potential for Enhanced Quality of Life: Researchers linked the positive outcomes of metered cryospray to improvements in cilia function, lung repair mechanisms, and epithelial barrier integrity, suggesting potential long-term benefits for patients with chronic bronchitis.
CSA Medical Inc announced multiple presentations at the European Respiratory Society (ERS) Congress in Vienna detailing new clinical science supporting metered cryospray with the RejuvenAir System for the treatment of chronic bronchitis.
In a session entitled, “Cutting-edge concepts in interventional pulmonology: the future is here!” Christopher Orton, MBBS, PhD, MRCP, consultant respiratory physician at Royal Brompton Hospital, London, UK, presented research characterizing potential mechanisms of action of bronchial epithelial resurfacing and remodeling utilizing metered cryospray for the treatment of patients with COPD with chronic bronchitis.
In addition to confirming the clinical efficacy of metered cryospray to reduce the symptoms associated with chronic bronchitis, he and his colleagues found a reduction in air-trapping and changes in cellular populations indicative of airway remodeling or “rejuvenation.”
Using Liquid Nitrogen
The RejuvenAir System, an investigational device not currently commercially available in the United States, targets the underlying chronic cough, dysfunctional mucus production, and clearance in chronic bronchitis. The RejuvenAir System applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient, or same-day bronchoscopic procedure.
The RejuvenAir System is designed to ablate these damaged cells, enabling a rejuvenative healing response.
Rejuvenative Healing Demonstrated
Building on the mechanism of action dataset, Orton’s co-investigators at the National Heart and Lung Institute (NHLI), Imperial College London presented further evidence of rejuvenative healing after metered cryospray treatment, concluding that the metered cryospray procedure reduced abnormal lung epithelium morphology and altered DNA methylation pathways suggesting a link between the regeneration of epithelial tissues in large airways and improvements in quality of life.
“Our initial transcriptomic analyses suggest that these increases in quality of life post-metered cryospray treatment may be associated with an improvement in cilia function and lung repair mechanisms and reduced epithelial to mesenchymal transition leading to an enhancement in epithelial barrier integrity,” says Pankaj Bhavsar, PhD, scientific lead at the NHLI, in a release.
Wendelin Maners, chief executive officer of CSA Medical, adds in a release, “We want to thank the clinicians and researchers at Imperial College London investigating the science behind tissue rejuvenation in chronic bronchitis patients who received metered cryospray therapy with RejuvenAir. The science reinforces the statistically significant clinical outcomes from previous studies, and we look forward to seeing more positive data from our larger SPRAY-CB pivotal trial next year.”
ID 179113175 © Konevaelvira | Dreamstime.com
